Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicola Benjamin

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Genes|May 28, 2022
Reduction of <i>BMPR2</i> mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?Vivienne Theobald, Nicola Benjamin, Hans-Jürgen Seyfarth, et al.
ESC Heart Failure|June 16, 2022
Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centresMax Wissmüller, Panagiota Xanthouli, Nicola Benjamin, et al.
Arthritis Research & Therapy|March 9, 2023
Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertensionPanagiota Xanthouli, Ojan Gordjani, Nicola Benjamin, et al.
Pharmacological Research|November 7, 2016
Gender-related differences in pulmonary arterial hypertension targeted drugs administrationAlberto M Marra, Nicola Benjamin, Christina Eichstaedt, et al.
Annals of the Rheumatic Diseases|December 11, 2019
Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertensionPanagiota Xanthouli, Suzana Jordan, Nicklas Milde, et al.
International Journal of Molecular Sciences|May 14, 2020
Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension-A Genetic StudyChristina A Eichstaedt, Jeremias Verweyen, Michael Halank, et al.
Annals of the Rheumatic Diseases|December 17, 2020
Response to: ' Correspondence on 'Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension'' by Iudici <i>et al</i>Ekkehard Grünig, Nicola Benjamin, Panagiota Xanthouli, et al.
Pneumologie (Stuttgart, Germany)|October 6, 2025
[General Measures and Management of PAH in Special Conditions]Mona Lichtblau, Satenik Harutyunova, Hans Klose, et al.
Arthritis Research & Therapy|October 28, 2019
Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)Zixuan Pan, Alberto M Marra, Nicola Benjamin, et al.
International Journal of Cardiology|September 8, 2018
General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018Ekkehard Grünig, Nicola Benjamin, Ulrich Krüger, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Genes|May 28, 2022
Reduction of <i>BMPR2</i> mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?Vivienne Theobald, Nicola Benjamin, Hans-Jürgen Seyfarth, et al.
ESC Heart Failure|June 16, 2022
Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centresMax Wissmüller, Panagiota Xanthouli, Nicola Benjamin, et al.
Arthritis Research & Therapy|March 9, 2023
Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertensionPanagiota Xanthouli, Ojan Gordjani, Nicola Benjamin, et al.
Pharmacological Research|November 7, 2016
Gender-related differences in pulmonary arterial hypertension targeted drugs administrationAlberto M Marra, Nicola Benjamin, Christina Eichstaedt, et al.
Annals of the Rheumatic Diseases|December 11, 2019
Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertensionPanagiota Xanthouli, Suzana Jordan, Nicklas Milde, et al.
International Journal of Molecular Sciences|May 14, 2020
Myeloproliferative Diseases as Possible Risk Factor for Development of Chronic Thromboembolic Pulmonary Hypertension-A Genetic StudyChristina A Eichstaedt, Jeremias Verweyen, Michael Halank, et al.
Annals of the Rheumatic Diseases|December 17, 2020
Response to: ' Correspondence on 'Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension'' by Iudici <i>et al</i>Ekkehard Grünig, Nicola Benjamin, Panagiota Xanthouli, et al.
Pneumologie (Stuttgart, Germany)|October 6, 2025
[General Measures and Management of PAH in Special Conditions]Mona Lichtblau, Satenik Harutyunova, Hans Klose, et al.
Arthritis Research & Therapy|October 28, 2019
Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)Zixuan Pan, Alberto M Marra, Nicola Benjamin, et al.
International Journal of Cardiology|September 8, 2018
General measures and supportive therapy for pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018Ekkehard Grünig, Nicola Benjamin, Ulrich Krüger, et al.
Pageof 8